Allogeneic anti-CD7 CAR-T cells (BEAM-201)
24CT015, 25-023121, BTX-ALT-00
Phase 1 mab active
Quick answer
Allogeneic anti-CD7 CAR-T cells (BEAM-201) for T-Cell Acute Lymphoblastic Leukemia/Lymphoma is a Phase 1 program (mab) at Beam Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Beam Therapeutics
- Indication
- T-Cell Acute Lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 1
- Modality
- mab
- Status
- active